| Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. | |
| | |
MedLine Citation:
|
PMID: 20547927 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The plexiform lesion is the hallmark of severe pulmonary arterial hypertension. However, its genesis and hemodynamic effects are largely unknown because of the limited availability of lung tissue samples from patients with pulmonary arterial hypertension and the lack of appropriate animal models. This study investigated whether rats with severe progressive pulmonary hypertension developed plexiform lesions. METHODS AND RESULTS: After a single subcutaneous injection of the vascular endothelial growth factor receptor blocker Sugen 5416, rats were exposed to hypoxia for 3 weeks. They were then returned to normoxia for an additional 10 to 11 weeks. Hemodynamic and histological examinations were performed at 13 to 14 weeks after the Sugen 5416 injection. All rats developed pulmonary hypertension (right ventricular systolic pressure approximately 100 mm Hg) and severe pulmonary arteriopathy, including concentric neointimal and complex plexiform-like lesions. There were 2 patterns of complex lesion formation: a lesion forming within the vessel lumen (stalk-like) and another that projected outside the vessel (aneurysm-like). Immunohistochemical analyses showed that these structures had cellular and molecular features closely resembling human plexiform lesions. CONCLUSIONS: Severe, sustained pulmonary hypertension in a very late stage of the Sugen 5416/hypoxia/normoxia-exposed rat is accompanied by the formation of lesions that are indistinguishable from the pulmonary arteriopathy of human pulmonary arterial hypertension. This unique model provides a new and rigorous approach for investigating the genesis, hemodynamic effects, and reversibility of plexiform and other occlusive lesions in pulmonary arterial hypertension. |
| | |
Authors:
|
Kohtaro Abe; Michie Toba; Abdallah Alzoubi; Masako Ito; Karen A Fagan; Carlyne D Cool; Norbert F Voelkel; Ivan F McMurtry; Masahiko Oka |
Related Documents
:
|
18978137 - Pulmonary hypertension in copd. 15827267 - Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines i... 20956167 - Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: path... 1748437 - Fatal pulmonary arterial occlusive vascular disease following chemotherapy in a 9-month... 22154787 - Pulmonary root translocation in malposition of great arteries repair allows right ventr... 10391307 - Reversed "c" ministernotomy for aortic valve replacement. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-06-14 |
Journal Detail:
|
Title: Circulation Volume: 121 ISSN: 1524-4539 ISO Abbreviation: Circulation Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-06-29 Completed Date: 2010-08-03 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0147763 Medline TA: Circulation Country: United States |
Other Details:
|
Languages: eng Pagination: 2747-54 Citation Subset: AIM; IM |
Affiliation:
|
Department of Pharmacology, Center for Lung Biology, University of South Alabama, AL, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Anoxia Arteries / pathology Disease Models, Animal* Hypertension, Pulmonary / etiology, pathology* Lung / blood supply Rats Vascular Endothelial Growth Factor A / antagonists & inhibitors |
| Chemical | |
Reg. No./Substance:
|
0/Vascular Endothelial Growth Factor A |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Impact of collateral flow to the occluded infarct-related artery on clinical outcomes in patients wi...
Next Document: Long-Term Evaluation of the Risk of Recurrence After Cerebral Sinus-Venous Thrombosis.